

SEPL/SE/October/26-27

29th October 2026

**The General Manager,
Corporate Relations/Listing
Department**

BSE Limited

Floor 25, P.J. Towers,

Dalal Street,

Mumbai – 400 001

Scrip Code: 501423

The Manager,

Listing Department

National Stock Exchange of India Limited

Exchange Plaza, Plot No. C/1, G Block,

Bandra – Kurla Complex,

Bandra (E),

Mumbai – 400 051

Scrip Code: SHAILY

Sub: Q2 & H1 FY27 – Investor Presentation

Ref: Regulation 30 of the SEBI Listing Regulations, 2015

Dear Sir,

In continuation to our letter dated 22nd October 2026, regarding intimation of Earnings Call of the Company scheduled on Friday, 30th October 2026 at 04:00 p.m., IST, to discuss the operational & financial performance of the Company for the quarter and half year ended on 30th September 2026, kindly find enclosed herewith **Q2 & H1 FY27 Investor Presentation** of the Company.

A copy of the same is also available on our website www.shaily.com.

Kindly take the same on record.

Thanking You.

Yours truly,

For Shaily Engineering Plastics Limited

Harish Govind
Govind Punwani
Punwani
Harish Punwani

Digitally signed by Harish
Govind Punwani
Date: 2026.10.29 19:00:33
+05'30'

Company Secretary & Compliance Officer

M. No. A 50950

Encl: a/a



Shaily Engineering Plastics Ltd.

This presentation and the accompanying slides (the “Presentation”), which have been prepared by **Shaily Engineering Plastics Limited** (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the company’s ability to successfully implement its strategy, the Company’s future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cash flows, the Company’s market preferences and its exposure to market risks, as well as other risks. The Company’s actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections.



Key Performance Highlights

Healthcare

Semaglutide pens supply by the company

- Two new contracts signed for IP led platforms

Two-step Reusable Auto-Injector Pen launched for GLP-1 therapies

- Shaily AI Toby™ Reusable

Capacity Addition

- 25 Mn Pens capacity is expected to be added
- Automation machines received, currently under commissioning and validation stage

Abu Dhabi Facility

- Setting up of a Facility in Abu Dhabi for manufacturing Medical Devices
- Expected investment of AED 130–150 million (~ Rs.350 Crores)
- Strategic expansion to support global GLP-1 opportunity
- This facility is expected to add a capacity of 75 Mn pens annually

Consumer

Business confirmation received for

- New product from an existing home furnishing customer
- Increased volumes for existing product from home furnishing customer

Industrial

Business confirmation received for

- 7 new products on Power Tools
- New knobs from an Appliance customer

Other Update

Rating Upgrade by CARE Ratings

- Short Term Bank Facilities of Rs.35 Crs. upgraded to CARE A1+ from CARE A1

New Product Launch : Shaily AI Toby™ Reusable



Two-step reusable auto-injector platform for GLP-1 therapies



How it works

1

Single-use Syringe Pod

Holds the pre-filled syringe; replaced with each dose

2

Retained driver

The Pod attaches to a reusable driver kept by the patient

3

Two-step injection

Subcutaneous delivery with needle lockout after use

Why it matters

Compared with a fully disposable auto-injector



Less material

Only the Syringe Pod is single-use; the driver is reused



Lower energy use

Less device volume to manufacture for every dose



Lighter shipping

Smaller single-use units to transport



Smaller cold-chain load

Less device volume to keep refrigerated




A stronger sustainability case for a weekly GLP-1 therapy taken over years

Key Consolidated Financial Highlights – Q2 & H1 FY27




Revenues




Gross Profit Margin




EBITDA




EBITDA Margins*



Profit After Tax





Cash PAT#



(Rs. Cr.)


#Cash PAT includes PAT & Depreciation

Segment Wise Revenue Breakup




Improved traction in the healthcare segment has been the key driver for the overall growth of the business

Machine Utilization
Across Plants (%)




Revenue Analysis – Domestic vs. Exports


The shift in the domestic-export mix is primarily due to the growing Healthcare business, where supplies to Indian pharma customers ultimately cater to global markets.




RoCE




RoE



Fixed Asset Turnover



Total Debt / Equity



Consolidated Profit & Loss Statement



Particulars (Rs. Crs.)	Q2 FY27	Q2 FY26	Y-o-Y	H1 FY27	H1 FY26	Y-o-Y
Revenue	319.5	256.7	24%	600.2	503.3	19%
Raw Material	127.7	104.5		249.5	225.0	
Employee Expenses	34.8	26.3		67.6	51.2	
Other Expenses*	59.9	46.5		102.9	79.5	
Other Income	4.7	2.3		5.0	4.4	
EBITDA	101.8	81.7	25%	185.1	152.0	22%
EBITDA Margin	31.9%	31.8%	10 bps	30.8%	30.2%	60 bps
Depreciation	14.3	12.0		28.3	23.4	
Finance Cost	3.0	3.9		6.3	7.8	
PBT	84.5	65.8	28%	150.5	120.8	25%
PBT Margin	26.5%	25.6%	90 bps	25.1%	24.0%	110 bps
Tax	23.3	14.4		41.2	28.4	
PAT	61.3	51.3	20%	109.3	92.4	18%
PAT Margin	19.2%	20.0%	-80 bps	18.2%	18.4%	-20 bps
Cash PAT^	75.5	63.4	19%	137.6	115.8	19%
Cash PAT Margin	23.6%	24.7%	-110 bps	22.9%	23.0%	-10 bps

* Other Expenses include Power & Fuel costs; ^ Cash PAT = PAT + Depreciation

Consolidated Balance Sheet

Particulars (Rs. Crs.)	Sep-26	Mar-26
Non-Current assets		
Property, Plant and Equipments	612.7	574.0
Capital Work in Process	29.5	28.8
Intangible assets	40.4	43.8
Investments	0.0	0.0
Intangible assets under devp.	3.6	2.3
Financial Assets		
Loans	0.5	0.5
Other Non-Current Assets	59.7	42.0
Income tax assets	8.1	5.3
Total Non-Current Assets	754.6	696.6
Current Assets		
Inventories	163.4	150.8
Financial Assets		
Trade Receivables	273.9	214.8
Cash and Cash Equivalents	45.5	25.2
Loans	0.4	0.4
Other Current Assets	63.4	59.0
Total Current Assets	546.6	450.1
Total Assets	1,301.1	1,146.7

Particulars (Rs. Crs.)	Sep-26	Mar-26
Equity		
Equity Share Capital	9.2	9.2
Other Equity	825.5	707.5
Total Equity	834.7	716.7
Non-Current Liabilities		
Financial Liabilities		
Long-term borrowings	21.9	27.3
Deferred tax liabilities (net)	38.4	34.0
Other long-term liabilities	2.3	2.5
Long-term provisions	5.1	5.0
Total Non-Current Liabilities	67.6	68.9
Current Liabilities		
Short-term borrowings	155.3	146.7
Trade payables	107.5	85.9
Other financial liabilities	16.6	22.2
Other current liabilities	104.5	95.0
Short-term provisions	9.9	8.9
Current tax liabilities (net)	4.9	2.6
Total Current Liabilities	398.8	361.2
Total Equity and Liabilities	1,301.1	1,146.7

Consolidated Cash Flow Statement

Particulars (Rs. Crs.)	Sep-26	Sep-25
Profit Before Tax	150.5	120.8
Adjustments	35.4	31.4
Operating profit before working capital changes	185.9	152.1
Changes in working capital	-37.8	-24.9
Cash generated from operations	148.1	127.3
Direct taxes paid (net of refund)	-37.6	-28.8
Net Cash from Operating Activities	110.5	98.4
Net Cash from Investing Activities	-89.4	-89.6
Net Cash from Financing Activities	-0.7	-6.7
Net Change in cash and cash equivalents	20.4	2.2
Add: Cash & Cash equivalents at the beginning of the period	20.8	19.1
Closing Cash Balance	41.2	21.2

Enriching Lives Through Plastics




Shaily Engineering Plastics Limited is India’s largest exporter of plastics components. Established in 1987, the Company provides end-to-end solutions in plastic products and services, whilst delivering superior quality and value to all stakeholders.


The Company employs over 2,000+ employees and have over 200+ injection molding machines, with precise, high speed automated and robotic production lines.

Revenue* Rs. 991 Crores FY 26	7 Facilities in Gujarat 6 for Plastic 1 for Steel Furniture	Long-standing global relationships with marquee clients
200+ Injection moulding machines	Over 2,000 employees across 7 plants	De-risked Business Model





7 Facilities with over 200 molding machines ranging from 35 tons to 1,000 tons



Rania

- ❖ Export Oriented Unit
- ❖ Pharma (Dedicated ISO Class 8 clean room manufacturing facility)
- ❖ Others

Halol (GIDC)

- ❖ Automotive & Engineering

Halol

- ❖ Carbon Steel
- ❖ Plastic

Executive Chairman

Mr. Mahendra Sanghvi

Whole Time Director

Mrs. Tilottama Sanghvi

Managing Director

Mr. Amit Sanghvi

Executive Director

Mr. Laxman Sanghvi

Independent Director

Dr. Shailesh Ayyangar

Independent Director

Mr. Ranjit Singh

Independent Director

Mr. Samaresh Parida

Independent Director

Ms. Sangeeta Singh

LONG TERM BANK FACILITIES

Rs. 239.24 Crs. (reduced from Rs.239.62)

CARE A+ ; Outlook: Stable

Rating Action: Reaffirmed

SHORT TERM BANK FACILITIES

Rs. 35 Crs.

CARE A1+

Rating Action: Upgraded from CARE A1



Long and established track record in the plastic injection molding business along with experienced Promoters



Growth in Total operating income on the back of increased volumes & higher exports



Sustainable healthy operating margin along with strengthening leverage and debt coverage indicators



New business confirmations from existing clients along with addition of marquee clients across diversified industries



Sustainable healthy operating margin along with strengthening leverage and debt coverage indicators

Consolidated Historical Profit & Loss Statement



Particulars (Rs. Crs.)	FY26	FY25	FY24	FY23
Revenue	990.7	786.8	643.9	607.1
Raw Material	426.2	415.8	370.1	386.5
Employee Expenses	109.7	80.4	57.3	47.9
Other Expenses*	174.9	114.5	99.5	80.8
Other Income	7.8	2.3	6.5	4.5
EBITDA	287.7	178.4	123.4	96.4
EBITDA Margin	29.0%	22.7%	19.2%	15.9%
Depreciation	49.2	42.2	35.7	33.3
Finance Cost	15.9	16.9	17.9	17.9
PBT	222.6	119.3	69.8	45.2
PBT Margin	22.5%	15.2%	10.8%	7.4%
Tax	52.7	26.2	12.6	10.1
PAT	169.9	93.1	57.3	35.1
PAT Margin	17.2%	11.8%	8.9%	5.8%
Cash PAT^	219.1	135.3	93.0	68.5
Cash PAT Margin	22.1%	17.2%	14.4%	11.3%

* Other Expenses include Power & Fuel costs; ^ Cash PAT = PAT + Depreciation

Consolidated Historical Balance Sheet



Particulars (Rs. Crs.)	Mar-26	Mar-25	Mar-24	Mar-23
Non-Current assets				
Property, Plant and Equipments	574.0	459.1	435.4	347.9
Capital Work in Process	28.8	17.4	15.3	49.0
Intangible assets	43.8	42.1	38.0	19.0
Investments	0.0	0.0	0.0	0.0
Intangible assets under devp.	2.3	0.3	5.1	19.3
Financial Assets				
Loans	0.5	0.5	0.5	0.5
Other Non-Current Assets	42.0	23.9	18.3	17.2
Income tax assets	5.3	3.8	2.7	2.1
Total Non-Current Assets	696.6	547.0	515.3	455.0
Current Assets				
Inventories	150.8	137.8	83.6	73.0
Financial Assets				
Trade Receivables	214.8	171.7	117.4	91.9
Cash and Cash Equivalents	25.2	23.1	26.4	23.0
Loans	0.4	0.3	6.4	5.7
Other Current Assets	59.0	52.6	33.5	44.1
Total Current Assets	450.1	385.6	267.2	237.7
Total Assets	1,146.7	932.6	782.5	692.7

Particulars (Rs. Crs.)	Mar-26	Mar-25	Mar-24	Mar-23
Equity				
Equity Share Capital	9.2	9.2	9.2	9.2
Other Equity	707.5	538.5	450.0	392.2
Total Equity	716.7	547.7	459.2	401.4
Non-Current Liabilities				
Financial Liabilities				
Long-term borrowings	27.3	40.1	69.8	62.5
Deferred tax liabilities (net)	34.0	23.6	20.8	17.0
Other long-term liabilities	2.5	0.2	1.2	1.2
Long-term provisions	5.0	3.9	2.2	2.3
Total Non-Current Liabilities	68.9	67.8	94.1	83.1
Current Liabilities				
Short-term borrowings	146.7	147.6	138.5	124.3
Trade payables	85.9	99.0	68.7	53.4
Other financial liabilities	22.2	12.5	10.3	9.3
Other current liabilities	95.0	44.0	10.4	20.0
Short-term provisions	8.9	7.1	1.3	1.2
Current tax liabilities (net)	2.6	6.9	0.0	0.0
Total Current Liabilities	361.2	317.1	229.2	208.2
Total Equity and Liabilities	1,146.7	932.6	782.5	692.7

Consolidated Cash Flow Statement

Particulars (Rs. Crs.)	FY26	FY25	FY24	FY23
Profit Before Tax	222.6	119.3	69.8	45.2
Adjustments	69.3	56.6	58.2	51.4
Operating profit before working capital changes	292.0	175.9	128.0	96.6
Changes in working capital	-16.9	-48.3	-27.0	-0.6
Cash generated from operations	275.1	127.6	101.0	96.0
Direct taxes paid (net of refund)	-49.4	-17.5	-8.8	-6.0
Net Cash from Operating Activities	225.7	110.1	92.3	90.0
Net Cash from Investing Activities	-184.7	-71.3	-99.0	-100.9
Net Cash from Financing Activities	-39.3	-41.9	9.8	-5.1
Net Change in cash and cash equivalents	1.7	-3.1	3.1	-16.0
Add: Cash & Cash equivalents at the beginning of the period	19.1	22.2	19.1	35.1
Closing Cash Balance	20.8	19.1	22.2	19.1



Company :

Investor Relations Advisors :

Shaily Engineering Plastics Ltd.

CIN – L51900GJ1980PLC065554

Mr. Sanjay Shah, Chief Strategy Officer

sanjay@shaily.com

www.shaily.com

Strategic Growth Advisors Pvt. Ltd.

CIN – U74140MH2010PTC204285

Mr. Deven Dhruva / Ms. Krisha Shrimankar

deven.dhruva@sgapl.net / krisha.shrimankar@sgapl.net

+91 98333 73300 / +91 87797 99281

www.sgapl.net